

TachoSil SEALANT MATRIX

Interesting facts about Gynecological Surgery





TachoSil® – selected studies...

Clinical studies

Buda A, Fruscio R, Pirovano C et al. The use of TachoSil® for the prevention of postoperative complications after groin dissection in cases of gynecologic malignancy. *Int J Gynaecol Obstet.* 2012;117(3):217-9. doi: 10.1016/j.ijgo.2011.12.021. Epub 2012 Mar 15. PMID: 22424660.



Barranger E, Morel O, Akerman G et al. TachoSil® to reduce the morbidity of axillary lymph node dissection in breast cancer. *Breast Cancer Res.* 2007;9(1),SP21. https://doi.org/10.1186/bcr1727.



Di Monta G, Caracò C, Crispo A et al. Collagen sealant patch to reduce lymphatic drainage after lymph node dissection. *World J Surg Oncol.* 2012;10:275. doi: 10.1186/1477-7819-10-275. PMID: 23253298; PMCID: PMC3547788.



Fuglsang K, Dueholm M, Stæhr-Hansen E et al. Uterine healing after therapeutic intrauterine administration of TachoSil® (hemostatic fleece) in cesarean section with postpartum hemorrhage caused by placenta previa. *J Pregnancy.* 2012;2012:635683. doi: 10.1155/2012/635683. Epub 2012 Apr 24. PMID: 22619722; PMCID: PMC3348634.



Santulli P, Marcellin L, Touboul C et al. Experience with TachoSil® in obstetric and gynecologic surgery. *Int J Gynecol Obstet.* 2011;113(2):112-5. doi: 10.1016/j.ijgo.2010.11.019. Epub 2011 Mar 30. PMID: 21453918.



Tinelli A, Mynbaev OA, Tsin DA et al. Lymphocele prevention after pelvic laparoscopic lymphadenectomy by a collagen patch coated with human coagulation factors: a matched case-control study. *Int J Gynecol Cancer.* 2013;23(5):956-63. doi: 10.1097/IGC.0b013e31828e444. PMID: 23574881.



Wrobel A, Winkler I, Rechberger Tet al. Does intraoperative application of TachoSil® reduce the number of lymphoceles after pelvic lymphadenectomy? *Ginekol Pol.* 2022;93(4):278-283. doi 10.5603/GP.a2021.0065.



Case reports

Greenberg JA, Robinson JN, Carabuena JM et al. Use of a Fibrin Sealant Patch at Cesarean for Conservative Management of Morbidly Adherent Placenta. *AJP Rep.* 2018;8(4):e325-e327. doi: 10.1055/s-0038-1675848. Epub 2018 Nov 14. PMID: 30443434; PMCID: PMC6235679.



Hiramatsu Y. Cesarean Hysterectomy for Placenta Previa Accreta Using Retrograde Abdominal Hysterectomy Approaching from the Posterior Vaginal Wall. *Surg J (N Y).* 2021;7(1):S38-S45. doi: 10.1055/s-0041-1728752. PMID: 35036546; PMCID: PMC8752194.



Jang JH, Kyeong KS, Lee S et al. A case of spontaneous hemoperitoneum by uterine vessel rupture in pregnancy. *Obstet Gynecol Sci.* 2016;59(6):530-534. doi: 10.5468/ogs.2016.59.6.530. Epub 2016 Nov 15. PMID: 27896257; PMCID: PMC5120074.



Shirata I, Fujiwaki R, Takubo K et al. Successful continuation of pregnancy after repair of a midgestational uterine rupture with the use of a fibrin-coated collagen fleece (TachoComb®) in a primigravid woman with no known risk factors. *American Journal of Obstetrics & Gynecology.* 2007;197:4e7-e9. doi: 10.1016/j.ajog.2007.07.039.



Case examples


1 Use of TachoSil® for sufficient hemostasis after a caesarean section under full heparinization



Diffuse abdominal bleeding in the area of the rectus abdominis muscle was stopped by using 2 TachoSil® patches (3.0 x 2.5 cm).

Reference: According to information and estimates from Prof. Dr. Michael K. Bohlmann, Department of Gynecology and Obstetrics., MaHM, Mannheim University Hospital, Germany.

2 TachoSil® for better hemostasis and suture support after laparoscopic myoma enucleation




The application of an individually folded and trimmed TachoSil® (9.5 x 4.8 cm) in the suture area led to a better hemostasis of the large wound bed and the 15 muscle sutures.

Reference: According to information and estimates from Dr. Stefan Bettin, Department of Gynecology, St. Ansgar-Hospital Hörter, Germany.

...and case examples

Case examples

3 Use of TachoSil® for sufficient hemostasis after a radical abdominal hysterectomy



Persistent bleeding at the level of the roof of the ureters, posterior face of vesicouterine plica and on the external iliac veins were controlled by using 2 TachoSil® patches.

Reference: According to information and estimates from Dr. Palomo López, Gynecology and Obstetrics at University Hospital Guadalajara, Spain.


4 TachoSil® for sufficient hemostasis after rupture of a gestating rudimentary horn



After massive active bleeding and hemoperitoneum a satisfactory hemostasis and a hemodynamic stability were achieved by covering all of the uterine surface with TachoSil®.

Reference: According to information and estimates from Dr. Asensio Vicente, Gynecology and Obstetrics at Joan XXIII University Hospital, Tarragona, Spain.

5 Application of TachoSil® for sufficient hemostasis after radical mastectomy



After the extraction of a tumor (35 mm) in the upper external quadrant of the right breast the bleeding in the area of the pectoralis major muscle was stopped after placement of TachoSil®.

Reference: According to information and estimates from Dr. De Gracia Díaz, Gynecology and Obstetrics at University Hospital Guadalajara, Spain.

6 Use of a TachoSil® for sufficient sealing after axillary lymphadenectomy



After a complete axillary lymphadenectomy TachoSil® was applied. Postoperative lymphorrage or lymphocele/seroma formation was not observed.

Reference: According to information and estimates from Dr. Gurrea Almela, Gynecology and Obstetrics at General University Hospital Reina Sofia, Murcia, Spain.

TachoSil® – four versions, three sizes*

Illustrated in original size

TachoSil[®] SEALANT MATRIX



*Not all versions are available in all countries

TachoSil Sealant Matrix (5.5 mg per cm² of human fibrinogen, 2.0 IU per cm² of human thrombin)

Statement: Before prescribing, consult/refer to the full prescribing information. **Presentation:** An off-white sealant matrix. The active side of the matrix is coated with fibrinogen and thrombin, is marked by a yellow colour. Supplied, ready to use, in sterile packaging. **Legal Classification:** Restricted prescription only medicine. **Indications:** In adults and children from 1 month old, for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing, and for suture support in vascular surgery where standard techniques are insufficient; also, in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurosurgical procedures. **Dosage & Administration:** For epispleneal use only. Use is restricted to experienced surgeons. The quantity to be applied is governed by the size of wound area, and the underlying clinical need for the patient. In clinical studies, the individual dosages have typically ranged from 1-3 units (9.5 cm x 4.8 cm); application of up to 10 units has been reported. For smaller wounds, the smaller size matrices (4.8 cm x 4.8 cm or 3.0 cm x 2.5 cm) or the pre-rolled matrix (based on a matrix of 4.8 cm x 4.8 cm) is recommended. TachoSil should be used under sterile conditions and immediately after opening the inner sterile cover. Prior to application, the wound area should be cleansed, e.g. from blood, disinfectants and other fluids. For Flat TachoSil, the sterile package should be pre-moistened in saline solution and applied immediately. The yellow, active side of the matrix is applied to the bleeding/leaking surface and held against it with a gentle pressure for 3-5 minutes. For pre-rolled TachoSil, after removing from the sterile package, it should be applied immediately through the trocar without pre-moistening. The yellow, active side of the matrix is applied to the bleeding/leaking surface using e.g., a pair of cleansed forceps and held against it with a moist pad under gentle pressure for 3-5 minutes. Pressure is applied with moistened gloves or a moist pad. Avoid TachoSil sticking to surgical instruments, gloves or adjacent tissues covered with blood by cleansing them before application. After pressing TachoSil to the wound, the glove or the pad must be removed carefully. To avoid TachoSil from being pulled loose it may be held in place at one end, e.g. with a pair of forceps. In the case of stronger bleeding, it may be applied without pre-moistening, while also pressing gently to the wound for 3-5 minutes. The active side of TachoSil should be applied so that it extends 1-2 cm beyond the margins of the wound. If more than one matrix is used, they should overlap. TachoSil can be cut to the correct size and shaped if too large. In neurosurgery, TachoSil should be applied on top of the primary dura closure. **Contraindications:** Intravascular use; hypersensitivity to the active substances or to any of the excipients. **Warnings & Precautions:** No specific data available on the use of this product in gastrointestinal anastomoses surgery. Life threatening thromboembolic complications may occur if the preparation is applied intravascularly. Allergic type hypersensitivity reactions are possible, as with any protein product. If hypersensitivity reactions occur, the administration must be discontinued immediately. To prevent the development of tissue adhesions at undesired sites, ensure tissue areas outside the desired application area are adequately cleansed before administration. In the case of shock, the current medical standards for shock treatment should be followed. Standard

measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV and for the non-enveloped virus HAV. Measures may be of limited value against non-enveloped viruses such as parvovirus B19. Parvovirus B19 infection may be serious for pregnant women (foetal infection) and for individuals with immunodeficiency or increased erythropoiesis (e.g., haemolytic anaemia). It is recommended to record the name and the batch number of the product administered to the patient. Some cases of product non-adhesion issues have been reported in the form of lack of product adhesion / lack of efficacy. Correct product handling and application is required. **Interactions:** No interaction studies have been performed. Similar to comparable products or thrombin solutions, the sealant may be denatured after exposure to solutions containing alcohol, iodine, or heavy metals. Such substances should be removed to the greatest possible extent before applying the sealant. **Fertility, Pregnancy & Lactation:** Safety for use in human pregnancy or breastfeeding has not been established in the clinical studies. Only administer to pregnant and breastfeeding women if clearly needed. **Effects on Ability to Drive and Use Machines:** Not relevant. **Undesirable Effects:** Hypersensitivity or allergic reactions (in isolated cases these reactions may progress to severe anaphylaxis; some cases of product residue causing granuloma), thromboembolic complications may occur if used intravascularly, and adhesions and intestinal obstruction when used in abdominal surgery. Refer to the SmPC for details on full side effect profile and interactions. **Overdose information:** No case of overdose has been reported. **Interactions with Other Medicinal Products:** No interaction studies have been performed. Similar to comparable products or thrombin solutions, the sealant may be denatured after exposure to solutions containing alcohol, iodine or heavy metals (e.g., antiseptic solutions). Such substances should be removed to the greatest possible extent before applying the sealant. **Use in Special Populations:** Limited data are available to support efficacy and safety of TachoSil in the paediatric population. In clinical studies, a total of 36 paediatric patients aged 0-13 years were treated with TachoSil in hepatic surgery. **Pack Sizes:** Package with 1 matrix of 9.5 cm x 4.8 cm, Package with 2 matrices of 4.8 cm x 4.8 cm, Package with 1 matrix of 3.0 cm x 2.5 cm, Package with 5 matrices of 3.0 cm x 2.5 cm, Package with 1 pre-rolled matrix of 4.8 cm x 4.8 cm. Not all pack sizes may be marketed.

Marketing Authorisation Holder: Corza Medical GmbH, Speditionstraße 21, 40221 Düsseldorf, Germany
The full SmPC can be obtained from Corza Medical GmbH.
Marketing Authorisation Numbers: EU/1/04/277/001-005

Date of Revision of the Text: 8 May 2025
Link to Full SmPC or Prescribing information
© 2025 Corza Medical. All rights reserved.